Werewolf Therapeutics Inc (HOWL) - News Archive

Expanding the Horizons of Immunotherapy: Advances in Werewolf Therapeutics’ PREDATOR and INDUKINE Platforms The field of immunotherapy is witnessing a paradigm shift with groundbreaking innovations designed to enhance t...

Werewolf Therapeutics Showcases Promising Data for WTX-330 at SITC Annual MeetingIn a significant contribution to cancer immunotherapy, Werewolf Therapeutics has presented both preclinical and clinical data on its inves...

In the constant battle against cancer, new advancements in treatment options bring hope to patients and healthcare professionals alike. Werewolf Therapeutics, a biopharmaceutical company focused on developing innovative...

Werewolf Therapeutics, a leader in innovative biotherapeutic developments, is poised to present the latest clinical trial data of its groundbreaking candidate WTX-124 at the 2024 American Society of Clinical Oncology (A...

In a groundbreaking presentation at the AAI Annual Meeting, Werewolf Therapeutics unveiled their pioneering research, highlighting the immense potential of IL-10 INDUKINE molecules as a promising therapy for the treatme...

Werewolf Therapeutics Sets Strategic Outlook and Prioritizes Development of Clinical AssetsWerewolf Therapeutics, a leading biotechnology company, has recently provided a business update and outlined its strategic outlo...